New clinical decision-support work focused on aligning surgical choices with patient-reported outcomes, aiming to reduce variability in breast-conserving surgery versus mastectomy decisions. IDECIDE, described as embedding real patient quality-of-life data into a decision aid, tested near-perfect understandability and actionability with both patients and clinicians. A separate imaging update also targeted preoperative risk stratification, reporting PET/CT glycolysis measures that predict outcomes in EGFR-mutant lung cancer patients on targeted therapy. Together, the studies illustrate a convergence: combining interpretable imaging biomarkers with decision frameworks rather than treating risk scoring as an end in itself. For clinical teams, the practical impact is that oncology pathways may increasingly rely on tools that translate biomarker signals into choice-specific outcomes, rather than relying on clinician judgment alone.